Skip to content

Evaluation of cumulative steroid doses in adult nephrotic syndrome

Optimizing duration of corticosteroid therapy in adult steroid sensitive nephrotic syndrome due to primary minimal change disease(MCD) /focal segmental glomerulosclerosis(FSGS) â?? a prospective open label randomized controlled trial(RCT)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033110
Enrollment
150
Registered
2021-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N00-N99- Diseases of the genitourinary system

Interventions

Intervention1: Early withdrawal of corticosteroid therapy: Adult (â?¥18 years) patients with nephrotic syndrome due to primary MCD/FSGS who achieved remission (SSNS) when treated for the first time wi

Sponsors

Funding applied for
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult (>=18 years) patients with NS due to primary MCD/FSGS who achieved remission (SSNS) when treated for the first time with oral prednisolone 1mg/kg/day for at-least 4 weeks and a maximum duration of 16 weeks.

Exclusion criteria

Exclusion criteria: 1) eGFR (2) Nephrotic range proteinuria without nephrotic syndrome (3) Presence of other concomitant diseases on kidney biopsy (4) Secondary cause of MCD and FSGS (5) Concomitant systemic disease like diabetes, hepatitis B or C or HIV infection (6) Prior treatment with immunosuppression for NS (7) Prior treatment with immunosuppression for any other indication in the past 6 months (8) Patients who have concomitantly received other immunosuppressive drugs in addition to prednisolone for initial treatment of the NS

Design outcomes

Primary

MeasureTime frame
The primary outcome studied will be the incidence of relapse during or after withdrawing steroids during the follow up period of one year from the initiation of tapering of steroids.Timepoint: Time points at which patients will be assessed after randomization- every month for a period of 12 months

Secondary

MeasureTime frame
The secondary outcome studied will be the (1) mean number of relapses in the two groups (2) proportion of patients with frequent relapse (3) frequency of late steroid resistance in relapsing patients (4) renal survival free of 50% decline in eGFR or progression to ESKD (5) The incidence and type of adverse effects.Timepoint: 12 months follow up after randomization

Countries

India

Contacts

Public ContactSoumita Bagchi

All India Institute of Medical Sciences

soumita_bagchi@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026